NCT07164482Available不适用
"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs for the Treatment of Patients With Traumatic or Nontraumatic Brain Injury"
Hope Biosciences Research Foundation2 个研究点 分布在 1 个国家开始时间: 2025年9月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
- 发起方
- 试验地点
- 2
研究概览
简要总结
This expanded access protocol is part of IND 031942 to evaluate efficacy and safety of multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of nontraumatic or traumatic brain injury for up to 8 patients who passed pre-screening, completed screening, and were not randomized into the treatment group for the HBBI01 clinical study protocol entitled, "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs for the Treatment of Patients with Traumatic or Nontraumatic Brain Injury." under IND 027396.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 14 Years 至 78 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients 14 - 78 years of age
- •Patient should provide evidence of TBI or non -TBI as evidenced by documentation in their medical records and imaging that was done within the past 3 years.
- •Female participants of childbearing potential should not be pregnant or plan to become pregnant during protocol participation and for 6 months after the last investigational product administration. Female participants of childbearing potential should confirm the use of one of the following contraceptive measures:
- •Hormonal contraceptives associated with ovulation inhibition (oral, injectable, implantable, patch, or intravaginal).
- •Intrauterine device (IUD), or intrauterine hormone-releasing system (IUS).
- •Barrier contraceptive methods (condoms, diaphragm, etc.).
- •Surgery (occlusion bilateral tubal ligation, hysterectomy, vasectomized partner).
- •Male participants if their sexual partners can become pregnant should ensure the use one of the following methods of contraception during protocol participation and for 6 months after the last administration of the investigated product:
- •Hormonal contraceptives associated with ovulation inhibition (oral, injectable, implantable, patch, or intravaginal).
- •Intrauterine device (IUD), or intrauterine hormone-releasing system (IUS).
- •Barrier contraceptive methods (condoms, diaphragm, etc.).
- •Surgery (vasectomy, occlusion bilateral tubal ligation (partner), hysterectomy (partner)).
- •Patient/LAR should be able to read, understand, and to provide voluntary consent.
排除标准
- •Women who are currently pregnant or lactating.
- •The patient has any active infection requiring medications per PI's discretion.
- •The patient has any clinical signs or symptoms of infection per PI's discretion.
- •The patient has hyperthermia or hypothermia.
- •The patient has any known recent (within the last 6 months) coagulation anomalies that are not being medically treated and are not stable per PI's discretion.
- •The patient has any abnormal laboratory values at the screening visit which the Investigator determines to be clinically significant and make the patient unsuitable for participation.
- •The Investigator determines the patient to be unsuitable for participation for other reasons, such as, but not limited to deep vein thrombosis (DVT), pulmonary embolus, cardiac arrhythmia, or those who have a prothrombotic condition, or who require persistent oxygen supplementation.
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Intermediate Size Expanded Access Protocol Using Autologous HB-adMSCs for the Treatment of Parkinson's DiseaseParkinson DiseaseNCT06056427Hope Biosciences Research Foundation
Unknown
不适用
Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 SyndromePost COVID-19 SyndromeNCT04798066Hope Biosciences Research Foundation
Approved For Marketing
不适用
Intermediate-Size Patient Population Expanded Access Program for Intravenous DifelikefalinUremic PruritusNCT05031546Cara Therapeutics, Inc.
Available
不适用
Expanded Access to Ensartinib for Participants With ALK+ NSCLCALK Gene Rearrangement PositiveNon-Small Cell Lung CancerNCT04146571Xcovery Holdings, Inc.
Unknown
不适用
Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease.Parkinson DiseaseNCT04772378Hope Biosciences Research Foundation